Sleep Number Receives Court Approval for Sale to Sleep Country Canada

This is now a recovery trade, not an operating equity story. Court approval meaningfully de-risks the buyer’s execution path, but it also narrows the range of plausible outcomes for the common: after secured debt, fees, lease-related claims, and transaction expenses, there is often very little left for equity in these situations. The market mistake would be pricing SNBR off headline “deal approved” optimism instead of the residual value waterfall.

The next 1-3 months are about document-level details, not macro demand: purchase price adjustments, assumed liabilities, rejected leases, employee/vendor claims, and any delay in closing. Each of those can leak value from the estate and compress recovery faster than the stock can re-rate upward. If the close slips beyond the stated window, uncertainty around cash burn and claims administration becomes the main downside catalyst.

Second-order, the buyer is the real winner: it can absorb a recognizable brand and operating platform without paying greenfield buildout costs. Competitive spillover to public peers is limited because this is a transfer, not an outright liquidation; any benefit to mattress and bedding comps would come only if the buyer rationalizes underperforming stores or reduces promotional intensity. The contrarian read is that the move may already be overinterpreted as “saved business,” while the equity may still be close to a zero-recovery claim once the full liability stack is finalized.